Search

Now showing items 1-10 of 31

Duration of immune protection of SARS-CoV-2 natural infection against reinfection.

Chemaitelly, Hiam; Nagelkerke, Nico; Ayoub, Houssein H; Coyle, Peter; Tang, Patrick; ... more authors ... less authors ( Oxford University Press , 2022 , Article)

The future of the SARS-CoV-2 pandemic hinges on virus evolution and duration of immune protection of natural infection against reinfection. We investigated duration of protection afforded by natural infection, the effect ...

Covid-19 Vaccine Protection among Children and Adolescents in Qatar.

Chemaitelly, Hiam; AlMukdad, Sawsan; Ayoub, Houssein H; Altarawneh, Heba N; Coyle, Peter; ... more authors ... less authors ( Massachusetts Medical Society , 2022 , Article)

The BNT162b2 vaccine against coronavirus disease 2019 (Covid-19) has been authorized for use in children 5 to 11 years of age and adolescents 12 to 17 years of age but in different antigen doses. We assessed the real-world ...

Protection against the omicron variant from previous SARS-CoV-2 infection

Altarawneh, Heba N.; Chemaitelly, Hiam; Hasan, Mohammad R.; Ayoub, Houssein H.; Qassim, Suelen; ... more authors ... less authors ( Massachusetts Medical Society , 2022 , Other)

Natural infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicits strong protection against reinfection with the B.1.1.7 (alpha),1,2 B.1.351 (beta),1 and B.1.617.2 (delta)3 variants. However, the ...

Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections.

Altarawneh, Heba N; Chemaitelly, Hiam; Ayoub, Houssein H; Tang, Patrick; Hasan, Mohammad R; ... more authors ... less authors ( Massachusetts Medical Society , 2022 , Article)

The protection conferred by natural immunity, vaccination, and both against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with the BA.1 or BA.2 sublineages of the omicron (B.1.1.529) ...

Effects of BA.1/BA.2 subvariant, vaccination, and prior infection on infectiousness of SARS-CoV-2 omicron infections.

Qassim, Suelen H; Chemaitelly, Hiam; Ayoub, Houssein H; AlMukdad, Sawsan; Tang, Patrick; ... more authors ... less authors ( Oxford University Press , 2022 , Article)

Compared to BA.1, BA.2 was associated with lower RT-qPCR cycle threshold (Ct) value-3.53 fewer cycles (95% CI: 3.46-3.60), signifying higher infectiousness. This may reflect higher viral load and/or longer duration of ...

Variations in respiratory syncytial virus activity following the relaxation of COVID-19 restrictions in Qatar.

Pérez-López, Andrés; Al Mana, Hassan; Iqbal, Muhammad; Suleiman, Mohammed; Hasan, Mohammad Rubayet; ... more authors ... less authors ( Oxford University Press , 2022 , Article)

Despite the relaxation of COVID-19 restrictions in Qatar in October-December 2020, the detection of RSV was reduced ∼25-fold compared with 2019. This dramatic decrease during the typical RSV season could be related to ...

Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar.

Chemaitelly, Hiam; Ayoub, Houssein H; AlMukdad, Sawsan; Coyle, Peter; Tang, Patrick; ... more authors ... less authors ( Nature Research , 2022 , Article)

SARS-CoV-2 Omicron BA.1 and BA.2 subvariants are genetically divergent. We conducted a matched, test-negative, case-control study to estimate duration of protection of the second and third/booster doses of mRNA COVID-19 ...

Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses.

Abu-Raddad, Laith J; Chemaitelly, Hiam; Yassine, Hadi M; Benslimane, Fatiha M; Al Khatib, Hebah A; ... more authors ... less authors ( Oxford University Press , 2021 , Article)

Strategies for rolling out vaccination against Coronavirus Disease 2019 (Covid-19) varied across countries. A key question is whether delaying administration of the second vaccine dose to vaccinate the largest number of ...

mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar

Chemaitelly, Hiam; Yassine, Hadi M.; Benslimane, Fatiha M.; Al Khatib, Hebah A.; Tang, Patrick; ... more authors ... less authors (2021 , Article)

The SARS-CoV-2 pandemic continues to be a global health concern. The mRNA-1273 (Moderna) vaccine was reported to have an efficacy of 94.1% at preventing symptomatic COVID-19 due to infection with ‘wild-type’ variants in a ...

Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar.

Chemaitelly, Hiam; Tang, Patrick; Hasan, Mohammad R; AlMukdad, Sawsan; Yassine, Hadi M; ... more authors ... less authors ( Massachusetts Medical Society , 2021 , Article)

Waning of vaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (Covid-19) is a concern. The persistence of BNT162b2 (Pfizer-BioNTech) vaccine ...